CHMP turns down new indication for Lilly's duloxetine, again
This article was originally published in Scrip
Lilly would have to submit a whole new application to the European Medicines Agency if it wanted to secure a new indication for three of its duloxetine products for treating moderate to severe chronic somatic pain in patients who do not regularly take NSAIDs.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.